Journal: Journal of clinical periodontology

Article Title: MFG-E8 inhibits periodontitis in non-human primates and its gingival crevicular fluid levels can differentiate periodontal health from disease in humans

doi: 10.1111/jcpe.12707

Figure Lengend Snippet: Three monkeys were treated as described in the legend to figure 1, and their mandibular bone heights (CEJ-ABC distance) were measured using Nikon Imaging System software and standardized X-ray images (taken at baseline and at week 6). Measurements were made at six points (first premolar, distal; second premolar, mesial and distal; first molar, mesial and distal; second molar, mesial) and the data in A and B reflect the 6-site total at baseline and at week 6, respectively. For each pair of Fc control and MFG-E8-Fc treatments, bone loss was calculated as bone height at baseline minus bone height at 6 week (C); the difference between Fc control and MFG-E8-Fc treatments was significant (P < 0.05; paired t test).

Article Snippet: The levels of MFG-E8 and various cytokines in collected GCF samples were measured using bead-based multiplex assays on a Bio-Plex system following the instructions of the manufacturers (R&D Systems, Minneapolis, MN, USA, for MFG-E8; EMD Millipore, Darmstadt, Germany, for cytokines).

Techniques: Imaging, Software

Journal: Journal of clinical periodontology

Article Title: MFG-E8 inhibits periodontitis in non-human primates and its gingival crevicular fluid levels can differentiate periodontal health from disease in humans

doi: 10.1111/jcpe.12707

Figure Lengend Snippet: Starting 3 days after initiation of ligature-induced periodontitis, MFG-E8-Fc or Fc control (both at 50 μg) were injected locally into the mandibular interdental papillae from the first premolar to the second molar, three times weekly, in opposite sides of the mouth (split-mouth design). The animals were clinically examined at the indicated timepoints and the effects of MFG-E8-Fc on the indicated inflammatory clinical parameters were recorded: (A) probing pocket depth (PPD), (B) gingival index (GI), (C) bleeding on probing (BOP), (D) mobility index (Mob), and (E) plaque index (PI). Data are means ± SD (n = 3 monkeys). *P < 0.05; **P < 0.01 compared with time-matched control (paired t test).

Article Snippet: The levels of MFG-E8 and various cytokines in collected GCF samples were measured using bead-based multiplex assays on a Bio-Plex system following the instructions of the manufacturers (R&D Systems, Minneapolis, MN, USA, for MFG-E8; EMD Millipore, Darmstadt, Germany, for cytokines).

Techniques: Injection

Journal: Journal of clinical periodontology

Article Title: MFG-E8 inhibits periodontitis in non-human primates and its gingival crevicular fluid levels can differentiate periodontal health from disease in humans

doi: 10.1111/jcpe.12707

Figure Lengend Snippet: GCF was collected from 40 subjects classified as either periodontally healthy or as having plaque-induced gingivitis, chronic moderate periodontitis, or chronic severe periodontitis. GCF was sampled from a total of 200 distinct sites (5 sites per individual; see Fig. 4 for site distribution among groups). Bead-based multiplex assays on a Bio-Plex system were used to assay the following molecules: (A) MFG-E8, (B) IL-1β, (C) IL-6, (D) IL-17A, (E) RANKL and (F) OPG. Dots represent individual values from distinct sampled sites and each box in the box-and-whisker plots extends from the 25th to the 75th percentiles. **P < 0.01; ****P < 0.0001 between indicated groups (Repeated measures analysis as implemented in SAS Proc GENMOD). ND, not detectable; NS, not significant.

Article Snippet: The levels of MFG-E8 and various cytokines in collected GCF samples were measured using bead-based multiplex assays on a Bio-Plex system following the instructions of the manufacturers (R&D Systems, Minneapolis, MN, USA, for MFG-E8; EMD Millipore, Darmstadt, Germany, for cytokines).

Techniques: Multiplex Assay, Whisker Assay

Journal: Journal of clinical periodontology

Article Title: MFG-E8 inhibits periodontitis in non-human primates and its gingival crevicular fluid levels can differentiate periodontal health from disease in humans

doi: 10.1111/jcpe.12707

Figure Lengend Snippet: GCF was collected from 5 subjects classified as having chronic severe periodontitis at baseline, at a re-assessment appointment following non-surgical periodontal treatment (SRP) and after pocket reduction surgery. GCF was sampled from a total of 30 distinct sites (6 sites per individual). Bead-based multiplex assays on a Bio-Plex system were used to assay the following molecules: (A) MFG-E8, (B) IL-6, (C) IL-17A, and (D) RANKL. (E) Measured deep probing pocket depths (PPD) before and after treatments. In A-D, dots represent individual values from distinct sampled sites and each box in the box-and-whisker plots extends from the 25th to the 75th percentiles. In E, data are means ± SD (n = 30 sites). **P < 0.01; ****P < 0.0001 between indicated groups (Repeated measures analysis as implemented in SAS Proc GENMOD).

Article Snippet: The levels of MFG-E8 and various cytokines in collected GCF samples were measured using bead-based multiplex assays on a Bio-Plex system following the instructions of the manufacturers (R&D Systems, Minneapolis, MN, USA, for MFG-E8; EMD Millipore, Darmstadt, Germany, for cytokines).

Techniques: Multiplex Assay, Whisker Assay

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: Serum MFG-E8 levels in patients with liver diseases. Serum milk fat globule-EGF factor 8 (MFG-E8) levels are shown for healthy volunteers (HVs) and hepatocellular carcinoma (HCC) patients ( A ), for HCC patients stratified by tumor size ( B ) by etiology of liver diseases ( C ), for hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected, post-sustained virologic response (SVR) and non-alcoholic fatty liver disease (NAFLD) patients with chronic hepatitis (CH), liver cirrhosis (LC), and HCCs ( D ), and in patients with benign liver tumors (Benign), intrahepatic cholangiocarcinoma (ICC), or metastatic liver tumors derived from primary colon cancer (Meta) ( D ) and for HCC patients before and after surgery (solid line, n = 12) or radiofrequency ablation (dashed line, n = 7) ( E ). Box plots represent the interquartile range and whiskers show minimum and maximum values. The line in each box shows the median. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, † p < 0.0001 compared with HV by Kruskal-Wallis test with Dunn’s multiple comparison test. Paired Student’s t test was used for the analysis presented in ( E ).

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques: Virus, Infection, Derivative Assay, Comparison

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: ROC analyses of serum MFG-E8, AFP, and DCP levels and our prediction model for diagnosis of HCC patients. ( A ) Receiver operating characteristic (ROC) curves for distinguishing hepatocellular carcinoma (HCC) patients (n = 185) from chronic hepatitis (CH)/ liver cirrhosis (LC) patients (n = 108). The optimal cutoff value for milk fat globule-EGF factor 8 (MFG-E8) was determined as those yielding the minimal value for (1 − sensitivity) 2 + (1 − specificity) 2 . ( B ) Venn diagram presenting the distribution of HCC patients according to MFG-E8, α-fetoprotein (AFP), and des-γ-carboxy prothrombin (DCP). ( C,D ) Performance assessment of our prediction model and other HCC tumor biomarkers for HCC for distinguishing HCC patients (n = 185) from CH/LC patients (n = 108) ( C ), and patients with HCCs smaller than 3 cm (n = 77) from CH/LC patients (n = 108) ( D ). AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: The relationship between serum preoperative MFG-E8 levels and HCC recurrence or survival following hepatectomy. ( A ) Kaplan–Meier analysis of overall survival (OS) for patients stratified by early recurrence (ER) within 1 year of resection (n = 54) and no recurrence within 1 year of resection (n = 131). ( B ) Serum milk fat globule-EGF factor 8 (MFG-E8) levels for preoperative hepatocellular carcinoma (HCC) patients grouped by early recurrence (ER; n = 54), late recurrence (LR; n = 52), and no recurrence (NR; n = 79). (C,D) Kaplan–Meier analysis of disease free survival (DFS) ( C ) and overall survival (OS) ( D ) for HCC patients stratified by serum MFG-E8 levels (cut-off: 3.42 ng/mL). Box plots show the interquartile range and whiskers show the minimum and maximum values. The line in each box shows the median. *p < 0.05.

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: Correlation between serum MFG-E8 level and clinicopathological features in 185 HCC patients.

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: Factors associated with early recurrence after hepatectomy for HCC (n = 185).

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: Factors associated with overall survival after hepatectomy for HCC (n = 185).

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques:

Journal: Scientific Reports

Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

doi: 10.1038/s41598-019-52356-6

Figure Lengend Snippet: Serum MFG-E8 levels and EVs in HVs and HCC patients. ( A ) Extracellular vesicles (EVs) isolated using the Tim4 affinity method were analyzed by nanoparticle tracking analysis (NTA) using NanoSight LM10. ( B ) Expression of the EV markers CD63, CD9, CD81 and flotillin 1 by western blotting. Full-length blots are presented in Supplementary Fig. . ( C ) Comparision of serum milk fat globule-EGF factor 8 (MFG-E8) levels before and after EV isolation by the Tim4 affinity method. ( D ) Correlation between serum MFG-E8 levels and the concentration of serum EVs isolated using the Tim4 affinity method. Sera were drawn from healthy volunteers (HVs) (n = 20) and hepatocellular carcinoma (HCC) patients (n = 20). ( E ) Comparative analysis of serum EVs from HVs and HCC patients by NTA. ( F ) EVs isolated using the ultracentrifugation method were analyzed by NTA using NanoSight LM10. ( G ) Comparative analysis of serum EVs isolated by the ultracentrifugation method from HCC patients (n = 15) and HVs (n = 15). *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal-Wallis test with Dunn’s multiple comparison test.

Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Techniques: Isolation, Expressing, Western Blot, Concentration Assay, Comparison

Journal: Acta diabetologica

Article Title: A rare missense variant in the milk fat globule-EGF factor 8 (MFGE8) increases T2DM susceptibility and cardiovascular disease risk with population-specific effects

doi: 10.1007/s00592-019-01463-x

Figure Lengend Snippet: a The distribution of circulating Mfge8 concentrations by MFGE8 genotypes. b The distribution of serum triglyceride levels by MFGE8 genotypes. p values are from the analysis of covariance (ANCOVA) showing difference between group means after adjusting for the confounding effects of age, gender, and BMI. Serum Mfge8 measures were available in 78 subjects including 39 T2DM cases and age- and gender-matched 39 controls

Article Snippet: Circulating concentrations of Mfge8 levels were quantified using frozen serum aliquots by enzyme-linked immunosorbent assay (ELISA) kits from Boster Biological Technology (Pleasanton, CA, USA) following the standard protocols following manufacturer’s instructions. ( www.bosterbio.com ).

Techniques:

Journal: Acta diabetologica

Article Title: A rare missense variant in the milk fat globule-EGF factor 8 (MFGE8) increases T2DM susceptibility and cardiovascular disease risk with population-specific effects

doi: 10.1007/s00592-019-01463-x

Figure Lengend Snippet: Multivariate regression analysis showing interactions between [T2DM status * Mfge8 concentrations] and [MFGE8 genotype * Mfge8 concentrations] for affecting triglyceride levels

Article Snippet: Circulating concentrations of Mfge8 levels were quantified using frozen serum aliquots by enzyme-linked immunosorbent assay (ELISA) kits from Boster Biological Technology (Pleasanton, CA, USA) following the standard protocols following manufacturer’s instructions. ( www.bosterbio.com ).

Techniques:

Journal: Acta diabetologica

Article Title: A rare missense variant in the milk fat globule-EGF factor 8 (MFGE8) increases T2DM susceptibility and cardiovascular disease risk with population-specific effects

doi: 10.1007/s00592-019-01463-x

Figure Lengend Snippet: Distribution of rs371227978 ( MFGE8 ) genotypes and allele frequencies in study samples stratified by diabetes status and association testing using logistic regression modeling

Article Snippet: Circulating concentrations of Mfge8 levels were quantified using frozen serum aliquots by enzyme-linked immunosorbent assay (ELISA) kits from Boster Biological Technology (Pleasanton, CA, USA) following the standard protocols following manufacturer’s instructions. ( www.bosterbio.com ).

Techniques:

Journal: Acta diabetologica

Article Title: A rare missense variant in the milk fat globule-EGF factor 8 (MFGE8) increases T2DM susceptibility and cardiovascular disease risk with population-specific effects

doi: 10.1007/s00592-019-01463-x

Figure Lengend Snippet: Multivariate linear regression analysis modeling showing genotype–phenotype association of MFGE8 variant for affecting serum Mfge8 concentrations

Article Snippet: Circulating concentrations of Mfge8 levels were quantified using frozen serum aliquots by enzyme-linked immunosorbent assay (ELISA) kits from Boster Biological Technology (Pleasanton, CA, USA) following the standard protocols following manufacturer’s instructions. ( www.bosterbio.com ).

Techniques: Variant Assay